Patient Human Clinical Trial Inquiries
Thank you for your interest in EBC-46 (tigilanol tiglate). QBiotics is not able to provide treatment with tigilanol tiglate at this time. Recruitment for our two Phase I/IIA safety studies in Australia and New Zealand is now closed and QBiotics does not currently have any other open trials. QBiotics will proceed to analyse and report on the Phase I/IIA studies, and then make a determination on how best to continue with clinical development for eventual approval of tigilanol tiglate as a human anticancer drug. Details of any future clinical trials will be posted on the company’s website and international clinical trial registries, such as ClinicalTrials.gov. We are developing the drug as quickly as possible so that, if development is successful, we can make tigilanol tiglate broadly available to those in need.
Please note that:
- QBiotics is not involved in assessing patients or recommending eligibility – this is something only the independent treating clinicians can determine.
- QBiotics staff are unable to discuss any aspects of these trials with potential patients and unfortunately we cannot respond to emails or phone requests for information about these clinical trials from the general public.